2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 12, 2019

9:00AM-11:00AM: Abstract Number: 2402

Which Factors Influence Achievement of Treatment Satisfaction in Rheumatoid Arthritis?

RA – Treatments Poster III: Safety and Outcomes

9:00AM-11:00AM: Abstract Number: 1962

Whole Transcriptome Analysis Maps Proinflammatory and Procoagulant Pathways in aPL Treated HUVECs

Genetics, Genomics & Proteomics Poster

9:00AM-11:00AM: Abstract Number: 2084

Why so Fast? A Focus on Reasons for an Increase in Arthritis-Attributable Activity Limitation Trends, 2002-2017

Epidemiology & Public Health Poster III: OA, Gout, & Other Diseases – ARP

9:00AM-11:00AM: Abstract Number: 2351

Withdrawal of Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Sarilumab Open-Label EXTEND Study: Efficacy and Safety Analysis

RA – Treatments Poster III: Safety and Outcomes

9:00AM-11:00AM: Abstract Number: 2525

Within-Trial Cost Analysis of Flares from a Phase 3 Clinical Trial Evaluating Subcutaneous Belimumab for the Treatment of Systemic Lupus Erythematosus

SLE – Clinical Poster III: Treatment

9:00AM-11:00AM: Abstract Number: 2384

Yoga Improves Fatigue and Mental Health in Rheumatoid Arthritis: Preliminary Results of a Randomized Controlled Trial

RA – Treatments Poster III: Safety and Outcomes

9:00AM-11:00AM: Abstract Number: 2429

Zipcode-Binding Protein 1 (ZBP1) Facilitates Ro60 Surface Translocation, Cellular Growth and Autoimmune Sequelae

Sjögrenʼs Syndrome – Basic & Clinical Science Poster I

11:00AM-12:30PM: Abstract Number: 2731

Decomposition Analysis of Spending and Price Trends for Biologic Anti-Rheumatic Drugs in Medicare and Medicaid

5T047: Plenary III (2727–2732)

11:00AM-12:30PM: Abstract Number: 2730

Efficacy and Safety of Romosozumab vs Placebo Among Patients with Mild-to-Moderate Chronic Kidney Disease

5T047: Plenary III (2727–2732)

11:00AM-12:30PM: Abstract Number: 2728

Efficacy and Safety of Upadacitinib in a Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 2/3 Clinical Study of Patients with Active Ankylosing Spondylitis

5T047: Plenary III (2727–2732)

11:00AM-12:30PM: Abstract Number: 2729

Ixekizumab in Non-Radiographic Axial Spondyloarthritis: Primary Results from a Phase 3 Trial

5T047: Plenary III (2727–2732)

11:00AM-12:30PM: Abstract Number: 2727

Mitochondrial Contribution to Juvenile Dermatomyositis Pathogenesis

5T047: Plenary III (2727–2732)

11:00AM-12:30PM: Abstract Number: 2732

The Relationship Between Gout and Cardiovascular Disease Outcomes: A Health Data Linkage Study of 1 Million New Zealanders Using Population-level Cardiovascular Risk Prediction Equations

5T047: Plenary III (2727–2732)

2:30PM-4:00PM: Abstract Number: 2776

5-years Treatment Effect of TNF Alpha Inhibitor in Early Axial Spondyloarthritis and Associated Factors: An Inverse Probability Weighting Analysis of the DESIR Cohort

5T094: Spondyloarthritis Including Psoriatic Arthritis – Clinical V: Axial Spondyloarthritis Clinical Studies (2774–2779)

2:30PM-4:00PM: Abstract Number: 2760

A Phase 2 Double-Blind Clinical Trial to Examine the Comparative Effects on Osteoarthritic Knee Pain of CGS-200-1 (1% Capsaicin Topical Liquid), CGS-200-5 (5% Capsaicin Topical Liquid), and CGS-200-0 (Vehicle, No Capsaicin)

5T090: Osteoarthritis – Clinical II: Novel Therapies (2756–2761)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].